Literature DB >> 3039830

Primary malignant mediastinal germ-cell tumors and the contribution of radiotherapy: a southeastern multi-institutional study.

C R Kersh, D R Eisert, W C Constable, S S Hahn, J M Jenrette, R H Fitzgerald, J Grayson.   

Abstract

A retrospective review was performed by a multi-institutional study group to determine the contribution of radiotherapy to the management of primary malignant mediastinal germ-cell tumors. Twenty-seven patients diagnosed with a primary mediastinal germ-cell tumor between January 1965 and July 1985 form the basis of this study. Twenty-five of the 27 patients were male. Thirteen patients' tumors were diagnosed as seminoma and the remaining 14 patients' tumors had other germ-cell histologies. The single most important prognostic factor was histology, with a 5-year actuarial survival of 100% for the seminomas and only 8.8% for the remaining germ-cell varieties. If total surgical extirpation is not possible, biopsy may be adequate. Of the patients with seminoma, 11 of 12 had local control, and 3 of the 12 patients were treated with doses between 3,000 and 3,100 cGy. High doses for this variety of mediastinal germ-cell tumor might not be required. For the germ-cell tumors other than seminoma, no patient had local control with doses over the range of 3,000-4,750 cGy.

Entities:  

Mesh:

Year:  1987        PMID: 3039830     DOI: 10.1097/00000421-198708000-00009

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Giant Mediastinal Germ Cell Tumour: An Enigma of Surgical Consideration.

Authors:  Firdaus Hayati; Nurayub Mohd Ali; Levin Kesu Belani; Nornazirah Azizan; Andee Dzulkarnaen Zakaria; Mohd Ramzisham Abdul Rahman
Journal:  Case Rep Surg       Date:  2016-10-11

2.  Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery.

Authors:  W J Childs; P Goldstraw; J E Nicholls; D P Dearnaley; A Horwich
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.